Sector News

NIH scientists move closer to vaccine holy grail: a universal flu shot

July 14, 2022
Life sciences

Researchers at the National Institutes of Health (NIH) are moving closer to the holy grail of the vaccine world: a universal flu shot.

An experimental vaccine from the NIH’s National Institute of Allergy and Infectious Diseases that protects against strains of influenza A virus in animal models is now moving into human studies. The shot has been shown to protect mice and ferrets from four strains of the influenza A virus, including potentially fatal strains from birds and pig, according to findings published July 13 in Science.

The seasonal flu causes as many as 650,000 global deaths each year. Because the virus mutates so quickly, a new vaccine must be developed every year, making it difficult to protect against the infection in the long term. Moreover, annual vaccines only fight circulating human strains and don’t offer protection against other strains that can emerge from animals.

To combat some of these issues, the NIH researchers developed a flu vaccine consisting of inactivated whole-virus avian subtypes of influenza A, which makes up most flu cases. Composed of subtypes H1N9, H3N8, H5N1 and H7N3, the vaccine also includes multiple viral proteins that trigger widely protective B- and T-cell responses.

The vaccine, which can be administered via injection or intranasally, protected mice and ferrets from various human, pig and bird flu strains. Compared to the control animals, vaccinated animals showed significant reductions in viral titers, lung pathology and host inflammatory responses.

The way the researchers created the vaccine is similar to current methods of production for seasonal flu vaccines, meaning manufacturing the candidate could be relatively simple and inexpensive. Additionally, no toxicity was observed in mice, ferrets or rabbits receiving the vaccine, suggesting that the candidate is likely safe in humans—although testing will, of course, be required.

The FDA has already approved an application to study the experimental vaccine in humans, with an initial phase 1 safety and immunogenicity study beginning this June at the NIH Clinical Center.

Researchers across the world have been attempting for years to develop a universal flu vaccine as it could spare scientists and pharmaceutical companies from the often inaccurate process of predicting the circulating strains each year and redesigning a vaccine to match them.

The new candidate could have broad application as both a prepandemic and a superseasonal flu vaccine that could be low-cost and easily distributed worldwide, the authors concluded.

By Gabrielle Masson


comments closed

Related News

March 19, 2023

Ferring Pharmaceuticals’ 1st in class C.diff Treatment, Rebyota, experiences a positive early launch ahead of potential competition

Life sciences

With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.

March 19, 2023

UCB enters drug discovery collaboration with Aitia

Life sciences

Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.

March 19, 2023

Novo, Medtronic add $25M in fuel to FIRE1 and its heart failure monitoring device

Life sciences

Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.

How can we help you?

We're easy to reach